MA30395B1 - Dérivés de thiazolidinedione utilisés comme inhibiteurs des kinases PI3 - Google Patents

Dérivés de thiazolidinedione utilisés comme inhibiteurs des kinases PI3

Info

Publication number
MA30395B1
MA30395B1 MA31349A MA31349A MA30395B1 MA 30395 B1 MA30395 B1 MA 30395B1 MA 31349 A MA31349 A MA 31349A MA 31349 A MA31349 A MA 31349A MA 30395 B1 MA30395 B1 MA 30395B1
Authority
MA
Morocco
Prior art keywords
thiazolidinedione derivatives
kinases
inhibitors
derivatives used
relates
Prior art date
Application number
MA31349A
Other languages
English (en)
Inventor
Michael Gerard Darcy
Steven David Knight
Nicholas D Adams
Stanley J Schmidt
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA30395B1 publication Critical patent/MA30395B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)

Abstract

L'invention concerne une méthode pour inhiber l'activité/ la fonction de kinases PI3 en utilisant des dérivés de thiazolidinedione. La présente invention concerne également une méthode pour le traitement d'un ou plusieurs états pathologiques choisis entre: des troubles auto-immuns, des maladies inflammatoires, des maladies cardio-vasculaires, des maladies neurodégénératives, l'allergie, l'asthme, la pancréatite, l'insuffisance d'organes multiples, des maladies rénales, l'agrégation plaquettaire, le cancer, la motilité du sperme, le rejet d'un transplant, le rejet d'un greffon et des lésions pulmonaires par administration de dérivés de thiazolidinedione.
MA31349A 2006-04-11 2008-11-03 Dérivés de thiazolidinedione utilisés comme inhibiteurs des kinases PI3 MA30395B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79113406P 2006-04-11 2006-04-11

Publications (1)

Publication Number Publication Date
MA30395B1 true MA30395B1 (fr) 2009-05-04

Family

ID=38723938

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31349A MA30395B1 (fr) 2006-04-11 2008-11-03 Dérivés de thiazolidinedione utilisés comme inhibiteurs des kinases PI3

Country Status (19)

Country Link
US (1) US20090306074A1 (fr)
EP (1) EP2004189A2 (fr)
JP (1) JP2009533467A (fr)
KR (1) KR20080108611A (fr)
CN (1) CN101466377A (fr)
AR (1) AR060391A1 (fr)
AU (1) AU2007253956A1 (fr)
BR (1) BRPI0710004A2 (fr)
CA (1) CA2649224A1 (fr)
CL (1) CL2007000995A1 (fr)
CR (1) CR10354A (fr)
EA (1) EA200870426A1 (fr)
IL (1) IL194575A0 (fr)
MA (1) MA30395B1 (fr)
MX (1) MX2008013174A (fr)
NO (1) NO20084457L (fr)
PE (1) PE20080038A1 (fr)
TW (1) TW200815429A (fr)
WO (1) WO2007136940A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255115A1 (en) * 2007-04-11 2008-10-16 Michael Gerard Darcy Thiazolidinedione derivatives as pi3 kinase inhibitors
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
GB0801416D0 (en) * 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
US20120245180A1 (en) 2009-09-28 2012-09-27 Glaxosmithkline Llc Combination
RU2458688C1 (ru) * 2011-06-23 2012-08-20 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ коррекции нарушений структурно-функциональных свойств эритроцитов и иммунного статуса у больных с острым панкреатитом
US10660882B2 (en) 2012-03-26 2020-05-26 Nippon Chemiphar Co., Ltd. Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma
JP6023630B2 (ja) * 2013-04-03 2016-11-09 株式会社ヤクルト本社 チアゾロン誘導体
JP6378918B2 (ja) * 2013-04-03 2018-08-22 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とするＰｉｍ阻害剤
KR20220000993A (ko) 2013-09-25 2022-01-04 닛뽕 케미파 가부시키가이샤 골·연부에 발생하는 거세포성 종양, 연골육종 또는 골육종의 예방, 치료 또는 전이 예방을 위한 약제, 동맥색전술용 국소 주입제 및 인공골
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
WO2019241789A1 (fr) 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Analogues de la rapamycine et leurs utilisations
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2195559A1 (fr) * 1994-08-10 1996-02-22 Takashi Sohda Derives de la thiazolidindione, leur procede d'obtention et leurs utilisations
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
AU2002252227A1 (en) * 2001-03-07 2002-09-24 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
EP1377976A2 (fr) * 2001-03-28 2004-01-07 Bayer Chemicals AG Support de donnees optique contenant dans la couche d'informations un colorant merocyanine en tant que compose photoabsorbant
US20050019825A9 (en) * 2002-03-15 2005-01-27 Qing Dong Common ligand mimics: pseudothiohydantoins
EP1501509A4 (fr) * 2002-04-30 2009-07-15 Merck & Co Inc Thiazolidine-dione et oxazolidine-dione a substitution aryle-liaison-aryle utiles en tant que bloqueurs des canaux sodiques
JP4782564B2 (ja) * 2002-07-10 2011-09-28 メルク セローノ ソシエテ アノニム アゾリジノン−ビニル縮合−ベンゼン誘導体
AU2003255529B2 (en) * 2002-07-10 2008-11-20 Laboratoires Serono Sa Use of compounds for increasing spermatozoa motility
US20040092561A1 (en) * 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
AU2003291024A1 (en) * 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US20060106077A1 (en) * 2003-07-18 2006-05-18 Pintex Pharmaceuticals, Inc. Pin1-Modulating compounds and methods of use thereof
ES2328146T3 (es) * 2003-07-28 2009-11-10 Merck Serono Sa 2-imino-4-(tio)oxo-5-policiclovinilazolinas para su uso como inhibidores de p13 quinasas.
US20050042213A1 (en) * 2003-08-14 2005-02-24 Insight Biopharmaceuticals Ltd. Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
ES2317238T3 (es) * 2004-07-01 2009-04-16 F. Hoffmann-La Roche Ag Quinolina-tiazolinonas con actividad antiproliferante cdk-1.
US7253285B2 (en) * 2004-09-17 2007-08-07 Hoffmann-La Roche Inc. Thiazolinone 4-monosubstituted quinolines
US20080255115A1 (en) * 2007-04-11 2008-10-16 Michael Gerard Darcy Thiazolidinedione derivatives as pi3 kinase inhibitors

Also Published As

Publication number Publication date
US20090306074A1 (en) 2009-12-10
CL2007000995A1 (es) 2008-06-27
EP2004189A2 (fr) 2008-12-24
NO20084457L (no) 2009-01-07
AR060391A1 (es) 2008-06-11
CA2649224A1 (fr) 2007-11-29
KR20080108611A (ko) 2008-12-15
AU2007253956A1 (en) 2007-11-29
TW200815429A (en) 2008-04-01
BRPI0710004A2 (pt) 2011-08-02
JP2009533467A (ja) 2009-09-17
IL194575A0 (en) 2009-08-03
MX2008013174A (es) 2008-10-21
WO2007136940A3 (fr) 2008-12-04
EA200870426A1 (ru) 2009-04-28
CR10354A (es) 2008-10-29
WO2007136940A2 (fr) 2007-11-29
PE20080038A1 (es) 2008-02-22
CN101466377A (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
MA30395B1 (fr) Dérivés de thiazolidinedione utilisés comme inhibiteurs des kinases PI3
MA34591B1 (fr) Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase
MA31443B1 (fr) Derives de quinoline en tant qu'inhibiteurs de pi3 kinase
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA30358B1 (fr) Quinazolines pour l'inhibition de pdk1
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA35285B1 (fr) Indazoles
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA54133B1 (fr) Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
MA31001B1 (fr) Quinazolines destines a l'inhibition de pdk
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MA30526B1 (fr) Inhibiteurs de prolyle hydroxylase
MA37450B1 (fr) Inhibiteurs d'indazole du trajet de signal de wnt et leurs utilisations thérapeutiques
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA29140B1 (fr) Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA38284B1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
MA38327A2 (fr) Dihydropyrimidinones bicycliques substituées et leur utilisation à titre d'inhibiteurs de l'activité élastase neutrophile
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.
TNSN07355A1 (fr) Derives d'aryl-1,4-pyrazine substitues
TNSN08138A1 (fr) Derives d'imidazole pour le traitement de troubles neurologiques